Search results

549 results

Sorted by Relevance . Sort by Date

In development Remove In development filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Medical technologies guidance Remove Medical technologies guidance filter
Diagnostics guidance Remove Diagnostics guidance filter
Public health guidelines Remove Public health guidelines filter
Social care guidelines Remove Social care guidelines filter
Medicines practice guidelines Remove Medicines practice guidelines filter

Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea [ID1065]

In development [GID-TA10385] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ravulizumab for treating atypical haemolytic uraemic syndrome (aHUS) [ID1530]

In development [GID-TA10564] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 alterations [ID3740]

In development [GID-TA10619] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Cabozantinib for previously treated advanced hepatocellular carcinoma [ID3917]

In development [GID-TA10805] Expected publication date: 23 March 2022

Type

Technology appraisal guidance

Status

In development
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy [ID3735]

In development [GID-TA10624] Expected publication date: 23 June 2021

Type

Technology appraisal guidance

Status

In development
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [ID1589]

In development [GID-TA10481] Expected publication date: 18 August 2021

Type

Technology appraisal guidance

Status

In development
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria [ID1457]

In development [GID-TA10690] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Fenfluramine for treating seizures associated with Dravet syndrome [ID1109]

In development [GID-TA10373] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Multiple myeloma and related disorders - Freelite assays (and alternative technologies identified during scoping) for diagnosis in primary care

In development [GID-DT28] Expected publication date: TBC

Type

Diagnostics guidance

Status

In development
Xpert MTB/RIF assay for the detection of active pulmonary tuberculosis and multi-drug resistant tuberculosis

In development [GID-DT9] Expected publication date: TBC

Type

Diagnostics guidance

Status

In development
KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)

In development [GID-DT14] Expected publication date: TBC

Type

Diagnostics guidance

Status

In development
DHT pilot: DECODE decision support system for the identification of dementia (Discontinued)

In development [GID-MT536] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
The Assurance Nasal Alar SpO2 Sensor (discontinued)

In development [GID-MT510] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Workplace health for employees with disabilities and long-term conditions

In development [GID-PHG58] Expected publication date: TBC

Type

NICE guideline

Status

In development
The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)

In development [GID-MT517] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
SeQuent Please Neo balloon catheter for in-stent coronary restenosis - update of MTG1 (discontinued)

In development [GID-MT516] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
OraQuick® HCV Rapid Antibody Test (discontinued)

In development [GID-MT117] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Levitronix CentriMag for treatment of refractory cardiogenic shock or severe cardiopulmonary insufficiency (discontinued)

In development [GID-MT130] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Clinitek Microalbumin 9 reagent strips for the early detection and monitoring of kidney disease (discontinued)

In development [GID-MT163] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Workplace health - older employees

In development [GID-PHG59] Expected publication date: 24 March 2016

Type

NICE guideline

Status

In development
Personal, social, health and economic education focusing on sex and relationships and alcohol education

In development [GID-PHG0] Expected publication date: TBC

Type

NICE guideline

Status

In development
Housing: planning to improve health and wellbeing

In development [GID-NG10053] Expected publication date: TBC

Type

NICE guideline

Status

In development
Microthane implants for breast reconstruction or breast augmentation (discontinued)

In development [GID-MT267] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
SILK artery reconstruction device (discontinued)

In development [GID-MT81] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Breast cancer (brain metastases) - etirinotecan pegol [ID881]

In development [GID-TA10066] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275

In development [GID-TA10375] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]

In development [GID-TA10363] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682]

In development [GID-TA10609] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Multiple sclerosis - sativex [ID387]

In development [GID-TAG368] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Avelumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID1146]

In development [GID-TA10341] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Atezolizumab with carboplatin or cisplatin and pemetrexed for untreated advanced non-squamous non-small-cell lung cancer ID1495

In development [GID-TA10395] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]

In development [GID-TA10380] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Idasanutlin with cytarabine for treating relapsed or refractory acute myeloid leukaemia [ID1597]

In development [GID-TA10494] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lenalidomide with R-CHOP for untreated activated diffuse large B-cell lymphoma [ID1611]

In development [GID-TA10480] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab for maintenance treatment of extensive stage small-cell lung cancer after chemotherapy ID1264

In development [GID-TA10365] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab for small-cell lung cancer after platinum-based chemotherapy [ID1126]

In development [GID-TA10158] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (ID1375)

In development [GID-TA10360] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]

In development [GID-TA10295] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]

In development [GID-TA10390] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Atezolizumab in combination for untreated squamous non-small-cell lung cancer [ID1481]

In development [GID-TA10546] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Durvalumab for untreated EGFR-negative, ALK-negative non-small-cell lung cancer ID1331

In development [GID-TA10318] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
PEGPH20 with nab-paclitaxel and gemcitabine for treating metastatic pancreatic cancer ID1502

In development [GID-TA10402] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nintedanib for untreated malignant pleural mesothelioma (ID1424)

In development [GID-TA10359] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies ID1455

In development [GID-TA10356] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]

In development [GID-TAG393] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Hypercholesterolemia - mipomersen [ID524]

In development [GID-TAG437] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Breast cancer (advanced or metastatic) - lapatinib [ID20]

In development [GID-TAG387] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]

In development [GID-TAG433] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Thrombophilia [ID393]

In development [GID-TAG374] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Systemic lupus erythematosus - prasterone [ID392]

In development [GID-TAG373] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development